CG Oncology (CGON) Enterprise Value (2023 - 2026)

CG Oncology (CGON) has 4 years of Enterprise Value data on file, last reported at -$1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 56.33% year-over-year to -$1.1 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.1 billion (down 56.33% YoY), and the FY2025 full-year result was -$742.2 million, changed 0.02% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.1 billion, down from -$742.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$187.7 million in Q4 2023 and bottomed at -$1.1 billion in Q1 2026.
• The 4-year median for Enterprise Value is -$670.7 million (2025), against an average of -$643.8 million.
• The widest annual swing landed in 2024, when Enterprise Value plunged 295.37%; it then slipped 0.02% in 2025.
• A 4-year view of Enterprise Value shows it stood at -$187.7 million in 2023, then slumped by 295.37% to -$742.0 million in 2024, then fell by 0.02% to -$742.2 million in 2025, then sank by 45.02% to -$1.1 billion in 2026.
• The last three Enterprise Value figures came in at -$1.1 billion (Q1 2026), -$742.2 million (Q4 2025), and -$680.3 million (Q3 2025), per Business Quant data.

Peer Comparison